Editorial note: TotalCareMedical.com is an independent health and wellness research publication. We are not a medical practice, do not employ clinicians, and do not provide medical advice. This is an editorial review of Refills as a consumer telehealth platform. Compounded GLP-1 medications dispensed through Refills are not FDA-approved finished drug products. Anyone considering prescription GLP-1 therapy should consult a qualified healthcare provider about eligibility, contraindications, and individual risks. Individual results vary.
Refills is a telehealth platform launched in April 2025 that markets prescription weight management — primarily compounded GLP-1 medications — through an online intake, virtual clinician review, and home-delivery pharmacy fulfillment. The category is crowded. The marketing across the category is, in many cases, structurally similar. What our editorial team does in every telehealth review is the work most reviews skip: trace the corporate structure, audit the actual pricing math beyond the landing-page promo, identify the dispensing pharmacy and partner clinician network, and read the disclaimers carefully enough to understand what the platform is and is not promising.
This review covers what Refills is, who actually prescribes and dispenses, what the program costs across promotional and standard tiers, the FDA compounded-medication context that most reviews bury in a footnote, and a candid take on who this platform realistically fits — and who should look elsewhere.
What Refills Is — and What It Explicitly Says It Is Not
Refills Health LLC is a Delaware-registered telehealth technology company headquartered at 1401 Pennsylvania Avenue, Suite 105, Wilmington, DE 19806. The company is reachable at 888-458-5061 and at support@refills.com. CEO Matt Osborn founded the platform in April 2025 with stated goals around accessibility, simplicity, and transparent pricing.
The structural disclosure on Refills' website is unusually direct, and reading it carefully matters: Refills is not a medical services provider. The assessment provided on the Refills website does not create a clinician–patient relationship between the user and Refills Health. Refills serves as a technology platform that connects users with independent licensed clinicians through partners such as Beluga Health, Bask Health, and Wasef Health. Refills does not manufacture or dispense any medications. All prescribing decisions are made solely at the discretion of the evaluating clinician.
This three-entity structure is common across modern telehealth, and Refills states it more clearly than most peers in the category. We cover what each layer actually does in our companion piece on how compounded semaglutide telehealth works at the platform, prescriber, and pharmacy layers.
The Three-Entity Model in Plain Language
The platform layer — Refills — operates the website, handles the intake form, manages customer service, processes billing, and coordinates between the other two layers. Refills cannot guarantee any individual user receives a prescription, because that determination belongs to the clinician.
The clinician layer is composed of independent licensed providers contracted through Beluga Health, Bask Health, and Wasef Health. These clinicians review the intake submitted through the Refills platform, evaluate eligibility against established medical protocols, and write prescriptions only when they determine treatment is clinically appropriate. If a clinician determines treatment is not appropriate, the user does not receive a prescription. That is a feature of legitimate telehealth, not a flaw.
The pharmacy layer fulfills approved prescriptions. Refills' terms currently identify Perfect Rx Pharmacy in Texas as a dispensing partner and note that additional partners may be added. The terms also permit a patient to direct their prescription to a pharmacy of their own choosing, with the understanding that the patient pays that outside pharmacy directly because the Refills platform price covers in-network fulfillment only.
What Refills Actually Offers
The headline category is GLP-1 weight management. Refills lists access to a Personalized GLP-1 (compounded semaglutide injection) along with brand-name medications including Ozempic, Wegovy, Zepbound, and Saxenda. Whether any individual user receives a brand-name prescription is determined by the evaluating clinician based on clinical appropriateness, availability, and the patient's medical profile.
Refills also operates outside GLP-1. The platform lists categories for Better Intimacy (sildenafil, tadalafil, and brand-name Viagra and Cialis), Daily Health (NAD+, sermorelin, methylene blue), and Hair Growth (oral finasteride, oral minoxidil, and a finasteride-and-minoxidil topical spray). For the purposes of this review, the focus stays on the weight management track because that is where the platform's marketing and the bulk of consumer search demand are concentrated.
The Refills Process from Intake to Delivery
The user-facing flow is straightforward. The patient creates an account on refills.com and completes a health intake covering medical history, current medications, weight history, and treatment goals. A licensed clinician within the partner network reviews the intake — Refills states this typically happens within 24 hours of submission, though timing varies. If the clinician determines GLP-1 therapy is appropriate, a personalized treatment plan is created. The prescription is routed to the dispensing pharmacy. Refills states tracking information is typically issued within two business days of approval and that most orders arrive within three to five business days after prescription approval and pharmacy processing.
Some Refills marketing pages reference free overnight shipping once a label is created. Other pages reference standard three-to-five-day shipping. The discrepancy is worth noting at intake — the consumer should confirm shipping terms at checkout for the specific offer they are entering through.
Pricing — and Why the Landing Page Number Is Not the Number
Refills' most prominent marketing offer is $159 for the first month, framed as an introductory rate. That number is real, and at the introductory price point Refills is aggressively positioned. The number that matters for budgeting, though, is the recurring monthly cost after the promotional period.
An official Refills landing page lists $399 per month for the program after the initial discount. That tier is described as including physician evaluations, follow-ups, unlimited clinician access, monthly prescriptions, a four-week supply of medication, any required blood work, and shipping. Other Refills pages advertise pricing as low as $6 per day when paid for a 12-month plan up front or financed through buy-now-pay-later. That pencils out to roughly $180 per month when averaged across the year — substantially below the $399 standard, comparable to the promotional first month, but requiring full annual prepayment or financing.
The honest budget assumption: plan for a $159 first month, then a recurring monthly spend somewhere in the $180 to $399 range depending on which Refills offer the user enters through and which plan they select. Pricing is subject to change and should be verified at refills.com before any purchase decision. We cover the full pricing math, including what each tier includes and what is not bundled, in our deep-dive on Refills GLP-1 pricing for 2026.
The FDA Compounded Disclaimer Is Substantive — Not Boilerplate
Refills states this directly on its website: compounded medications are dispensed by U.S. pharmacies that are highly regulated and inspected by State Boards of Pharmacy, but the FDA has not evaluated these compounded medications for safety, quality, or efficacy. This is the standard regulatory distinction between compounded preparations and FDA-approved finished drug products, and it is important.
Compounded semaglutide and compounded tirzepatide are prepared by licensed compounding pharmacies — typically operating under FDA Section 503A or 503B designations — using bulk active pharmaceutical ingredients. They are not the same product as Wegovy, Ozempic, Zepbound, or Mounjaro, even when they share an active molecule. The brand-name medications underwent the FDA's full review process for that specific finished formulation. The compounded versions did not. Compounded GLP-1s are also subject to ongoing regulatory and litigation activity, with enforcement timelines that have shifted over time.
None of this means compounded medications are unsafe by definition. Many are dispensed safely under appropriate clinical oversight. It does mean the consumer is not buying the same product they see in a Wegovy commercial, even when the marketing visually suggests an equivalence. That distinction belongs at the front of any honest review of any compounded GLP-1 platform — not in a footnote.
What the Trial Data Actually Shows for the Active Molecules
Compounded semaglutide and brand-name semaglutide share the active molecule. The peer-reviewed clinical trial data referenced across the category — STEP-1 in particular — was conducted using the brand-name finished product, not compounded versions. STEP-1, published in the New England Journal of Medicine in 2021, evaluated semaglutide 2.4 mg weekly in adults with overweight or obesity over 68 weeks. Average weight reduction was approximately 14.9 percent of baseline body weight in the medication arm, compared with 2.4 percent in the placebo arm, when combined with lifestyle intervention.
Tirzepatide trial data references a different molecule — a dual GIP/GLP-1 receptor agonist. SURMOUNT-1, published in 2022, evaluated tirzepatide at three dose levels over 72 weeks in adults with obesity. Average weight reduction at the highest studied dose was approximately 22.5 percent of baseline body weight.
The published trial data is real, peer-reviewed, and meaningful. Two important caveats: the trials were conducted on the brand-name finished products, and individual results vary substantially based on dose tolerance, lifestyle adherence, baseline metabolic profile, and treatment duration. Anyone evaluating outcomes should hold the trial averages as the upper boundary of what well-supervised treatment can achieve under controlled conditions, not as the expected result for any individual patient.
Refund, Cancellation, and What Happens If Something Goes Wrong
Refills' return policy reflects state and federal regulations governing prescription medications. Once a prescription has been dispensed by the pharmacy and handed to a carrier (USPS, FedEx, UPS), all sales on prescription items are final. Returns of dispensed prescription medications are not legally permitted. The user can log into their Refills account before a product is sent to the pharmacy to change address, change payment method, or cancel the subscription.
For non-prescription items, Refills accepts returns of unopened items within 30 days of sale. The customer pays return shipping, COD returns are not accepted, and the item must arrive in its original unopened condition.
If a prescription order arrives damaged or is lost in transit, Refills' patient care team coordinates with the carrier and will reship the order. The customer-service contact for both shipping issues and general support is 888-458-5061 or support@refills.com.
The Consumer Protection Reading — Where the Fine Print Lives
A few items from Refills' terms that any prospective customer should understand before submitting an intake:
Binding arbitration with class-action waiver. Disputes are resolved through individual arbitration; users waive the right to participate in a class action. This is increasingly standard across telehealth and direct-to-consumer health platforms but is worth seeing before signing up rather than after.
Prescription final-sale rule. Once medication is dispensed, refunds are not legally available. The window for cancellation is the period between order placement and the prescription being routed to the pharmacy.
Subscription auto-renewal. The Refills model is recurring. The subscription continues until canceled. Refills states cancellation is available online through the user dashboard at any time, but the consumer is responsible for canceling before the next charge if they want to stop service.
Pharmacy choice. Patients can direct prescriptions to a pharmacy of their choosing, but the platform price covers in-network fulfillment only. Out-of-network pharmacies are paid directly by the patient, which can change the total monthly cost meaningfully depending on the outside pharmacy's pricing.
Who Refills Realistically Fits
The platform fits a specific consumer profile clearly. The introductory $159 price point is among the most aggressive in the category, which makes Refills attractive for someone testing GLP-1 access at low first-month commitment before deciding whether ongoing therapy makes sense. The annual plan averaging around $180 per month is competitive for someone who has already decided GLP-1 is right for them and wants to lock in lower long-term cost in exchange for upfront commitment.
Refills is less ideal for someone who needs strong continuity of in-person care, someone who is uncertain about compounded versus brand-name medications and would benefit from a longer in-person consultation, or someone whose insurance covers brand-name GLP-1 through a traditional primary care or endocrinology referral. For that consumer, working with a primary care physician toward an FDA-approved branded prescription with insurance support is often the better long-term value, even if it requires more time and paperwork upfront.
It is also worth considering how Refills compares against other telehealth GLP-1 platforms operating in the same category. We cover that in our companion Refills vs SynergyRx comparison, and the broader category context lives on our Telehealth Platform Reviews hub. The safety profile of GLP-1 therapy itself — including contraindications, common side effects, and the questions any patient should bring to a clinician evaluation — is covered in our Refills GLP-1 side effects and safety piece.
Final Editorial Take
Refills is a structurally clear telehealth platform. The corporate disclosure is more direct than the category average. The pricing has multiple tiers, and the standard rate is meaningfully higher than the promotional rate, but Refills does not hide the standard rate — it is documented on the platform's own pages. The compounded GLP-1 disclaimer is present on the site and is not buried. The clinician network and dispensing pharmacy are identified, which is more transparency than several competitors offer.
Whether Refills is the right choice for any individual user is a clinical and financial question that belongs between the user and a licensed healthcare provider. What this review can say with confidence is that Refills' marketing claims line up with what the company's own terms and policies state, the pricing is real if more layered than the landing page implies, and the FDA compounded-medication context is something every prospective patient should understand before submitting an intake. The platform is what it presents itself as. Whether the platform's offering fits the patient is the patient's decision to make in consultation with a clinician.
For broader weight management context — including evidence-based natural strategies and the full editorial framework we apply to GLP-1 telehealth — see our Weight Management hub.